A Medical Device Daily

Phenomenex (Torrance, California), a worldwide supplier of separation science consumables, said it has entered a distribution agreement for Beckman Coulter ’s (Fullerton, California) ProteomeLab IgY enrichment products for proteomics and biomarker discovery.

The agreement grants Phenomenex exclusive distribution rights in the U.S., Canada and countries in the European Union.

Based on avian-generated antibodies, ProteomeLab IgY-12 liquid chromatography and spin columns are designed to offer cleaner capture and broader antigen-binding host range than other protein depletion/partitioning methods because of the evolutionary distance between chickens and mammals.

“Protein partitioning is a critical part of any biomarker discovery program and we view the ProteomeLab IgY products as the best available,” said Michael McGinley, Phenomenex Biochromatography Product Manager. “These columns fit well with our portfolio of complete proteomics solutions for the separation of proteins and peptides.”

Highly abundant proteins can significantly mask potential markers and impede the discovery of biomarker targets. ProteomeLab IgY-12 columns selectively partition 12 highly abundant proteins, up to 96% of the protein mass, from human/primate serum, plasma or cerebrospinal fluid. IgY-R7 columns partition 7 highly abundant rodent proteins, while single-component kits specifically capture a choice of seven key highly abundant plasma proteins, enabling a more targeted approach for specific protein partitioning. IgY delivers an enriched proteome that includes medium- and low-abundance proteins that are of interest to biomarker research.